At present, given the recent successes of mitogen-activated protein kinase inhibitors, as well as emerging data with other targeted therapies, we believe that VBL/MTX does not warrant further evaluation in children with NF1 and progressive and/or inoperable PN. Here, WNK2 is linked to poikiloderma with neutropenia.